Kendle will conduct a telephone conference call and simultaneous webcast on Tuesday, June 3 at 9:30 a.m. Eastern Time to discuss the acquisition of DecisionLine Clinical Research Corporation that was announced on May 30 and to provide an update on second quarter progress. A question and answer session will follow.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )
Webcast Instructions
To access the live webcast, go to www.kendle.com or http://www.videonewswire.com/event.asp?id=48934 . Instructions for accessing the webcast are provided at both sites. The webcast will be archived at www.kendle.com (click on “Investors” and then “Events & Presentations”) shortly after the call for on-demand replay through 5 p.m. Eastern Time on July 3, 2008. Please note that webcast participants will not be able to ask questions.
System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx .
Conference Call Instructions
To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 399-0069. Participants outside North America should dial (706) 643-3694. A replay will be available through 5 p.m. Eastern Time on July 3 by dialing (706) 645-9291 and entering conference ID number 50042856.
About Kendle
Kendle is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world’s biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services we offer experience spanning 90 countries, along with industry- leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers’ clinical development challenges. Kendle was named “Top CRO to Work With” in the Thomson CenterWatch 2007 survey of U.S. investigative sites and “Best CRO” for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202, United States or from the company’s Web site at www.kendle.com
CONTACT: Investors, Patty Frank, +1-513-763-1992; Media, Lori Dorer,
+1-513-345-1685, both of Kendle
Web site: http://www.kendle.com/
